HuMax-TF is a fully human antibody targeted to tissue factor (TF), a protein involved in tumor signaling and angiogenesis.
As per the deal, Genmab gets development and cGMP manufacturing plan to create ADC product targeting tissue factor (TF).
Lonza will take up process development and cGMP manufacturing for Genmab’s monoclonal antibody HuMax-TF in its Slough, UK facility.
The naked antibody will be conjugated by Lonza at its ADC plant in Visp, CH to a cytotoxic drug in order to form the antibody drug conjugate HuMax-TF.